Sculptor Capital’s CERo Therapeutics CERO Stock Holding History

Sculptor Capital’s Portfolio CERO Stock Details CERO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15	Closed	-$296K	–	902
2022 Q3	$296K	Hold	15	–	–	﹤0.01%	647
2022 Q2	$294K	Buy	15 +1	+7%	+$20K	﹤0.01%	707
2022 Q1	$276K	Buy	+14	New	+$279K	﹤0.01%	804

Other funds holding CERO

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Sculptor Capital's CERO Position: Q4 2022 in Review

Sculptor Capital sold out of CERo Therapeutics (CERO) in Q4 2022, closing a stake of 15 shares — an estimated $296K sold.

Sculptor Capital first reported a position in CERO in Q1 2022 and held it in 3 quarters. The position peaked at $296K in Q3 2022. 45 funds tracked by Wall St. Rank hold CERO as of Q4 2022.

Sculptor Capital reported no remaining CERo Therapeutics position as of Q4 2022 after selling out during the quarter.
Sculptor Capital sold 15 CERo Therapeutics shares in Q4 2022, an estimated $296K.
Sculptor Capital first reported a position in CERo Therapeutics in Q1 2022 and held it in 3 quarters.
Sculptor Capital's CERo Therapeutics position peaked at $296K in Q3 2022.
45 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2022.

Based on Sculptor Capital's 13F filing for Q4 2022, filed 14 Feb 2023.